Elavi Labs shares are trading higher after the company announced the launch of Elevai Biosciences and Elevai Skincare. Also, the company announced results from its licensor's 2022 preclinical studies evaluating the treatment effect of EL-22.

5/2/24 12:06:52 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ELAB alert in real time by email

Get the next $ELAB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ELAB

Date	Price Target	Rating	Analyst

More analyst ratings

$ELAB
Press Releases

Fastest customizable press release news feed in the world

CORRECTION - Elevai Labs Inc.
NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- In a release earlier today by Elevai Labs Inc. (NASDAQ:ELAB), please note that in the headline and first paragraph, the financial results are from the company's third fiscal quarter of 2024, not the second fiscal quarter as previously stated; as such, the header over the first bullet list should note the financial results as being from the three and nine months ended September 30, 2024, rather than the three and six months ended June 30, 2024 as previous stated. The corrected release follows: Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update Achieves Robust Financial Perfor
11/14/24 2:35:59 PM ET
$ELAB
Biotechnology: Pharmaceutical Preparations
Health Care
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources for Continued Growth and Innovation.Elevai Enfinity™ Clinical Trials Showcase Breakthroughs in Skin Firmness, Tone, and Wrinkle Reduction, Reinforcing Leadership in Aesthetic Innovation.Elevai Biosciences Expands Patent Portfolio with EL-22, a Myostatin-Targeting Treatment for Obesity, Addressing Muscle Preservation in Weight Management NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended September 30, 2024 and
11/14/24 9:08:00 AM ET
$ELAB
Biotechnology: Pharmaceutical Preparations
Health Care
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, announced today that it is has amended and restated the Offer to Exchange, including extending the expiration date, of its previously announced offer (the "Offer") to holders of the Company's outstanding Common Stock (the "Common Stock"), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock ("Series B Preferred Stock"), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock. The terms and conditions of the Offer are descr
11/4/24 5:45:39 PM ET
$ELAB
Biotechnology: Pharmaceutical Preparations
Health Care

Elavi Labs shares are trading higher after the company announced the launch of Elevai Biosciences and Elevai Skincare. Also, the company announced results from its licensor's 2022 preclinical studies evaluating the treatment effect of EL-22.

Chat with this insight

Recent Analyst Ratings for
$ELAB

$ELAB
Press Releases

Fastest customizable press release news feed in the world

CORRECTION - Elevai Labs Inc.

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

$ELAB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Bwl Investments Ltd. claimed ownership of 3,562,414 shares (SEC Form 3) (Amendment)

New insider Braeden Lichti claimed ownership of 1,906,414 shares (SEC Form 3) (Amendment)

$ELAB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Elevai Labs Inc.

SEC Form SC 13G filed by Elevai Labs Inc.

SEC Form SC 13G filed by Elevai Labs Inc.

$ELAB
Financials

Live finance-specific insights

Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

$ELAB
SEC Filings

Amendment: SEC Form SC TO-I/A filed by Elevai Labs Inc.

Elevai Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Elevai Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

$ELAB
Leadership Updates

Live Leadership Updates

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

$ELAB
Market Insights

Live Market Insights

Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Top 4 Risk Off Stocks You'll Regret Missing In July

Elevai Labs Inc. Announces CEO Jordan Plews' Intention To Resign Effective June 21

Elavi Labs shares are trading higher after the company announced the launch of Elevai Biosciences and Elevai Skincare. Also, the company announced results from its licensor's 2022 preclinical studies evaluating the treatment effect of EL-22.

Chat with this insight

Recent Analyst Ratings for $ELAB

$ELAB Press Releases

Fastest customizable press release news feed in the world

CORRECTION - Elevai Labs Inc.

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

$ELAB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Bwl Investments Ltd. claimed ownership of 3,562,414 shares (SEC Form 3) (Amendment)

New insider Braeden Lichti claimed ownership of 1,906,414 shares (SEC Form 3) (Amendment)

$ELAB Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Elevai Labs Inc.

SEC Form SC 13G filed by Elevai Labs Inc.

SEC Form SC 13G filed by Elevai Labs Inc.

$ELAB Financials

Live finance-specific insights

Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

$ELAB SEC Filings

Amendment: SEC Form SC TO-I/A filed by Elevai Labs Inc.

Elevai Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Elevai Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

$ELAB Leadership Updates

Live Leadership Updates

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

$ELAB Market Insights

Live Market Insights

Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Top 4 Risk Off Stocks You'll Regret Missing In July

Elevai Labs Inc. Announces CEO Jordan Plews' Intention To Resign Effective June 21

Recent Analyst Ratings for
$ELAB

$ELAB
Press Releases

$ELAB
Insider Trading

$ELAB
Large Ownership Changes

$ELAB
Financials

$ELAB
SEC Filings

$ELAB
Leadership Updates

$ELAB
Market Insights